Dr. Fan was trained at UC, Berkeley in Biostatistics and obtained his Doctor degree from Cornell/Sloan-kettering in structural
biology/Immunology. He was further trained by Dr. Gunter Blobel at Rockefeller University. With a dream of using
a hybrid approach (by combining computation design and experimental validation) to accelerate drug discovery,
and to reform current “hit-2-lead” drug discovery scheme, Dr. Fan founded Accutar biotech with the support of
Dr. Gunter Blobel. Dr. Fan also hold a joint appointment at SUNY, Downstate medical school as a research assistant
Wei He, Ph.D., brings to Accutar Biotechnology 11 years of oncology drug discovery experience in both small molecule and
biologics. Most recently, he was Associate Director of Preclinical Pharmacology at Incyte Corporation. In this
role, he oversaw cancer biology groups leading efforts of project initiation and progression to IND. Prior to
joining Incyte, Wei served as scientific project leader at Abbvie Oncology and Roche Oncology, where he led cross-functional
project teams working on immuno oncology, targeted therapy, antibody drug conjugate and therapeutic RNAi programs.
Wei obtained his B.S. and M.S. in chemistry from Peking University in China and his Ph.D. in biochemistry and
molecular biology from Baylor College of Medicine. He completed his HHMI postdoctoral training at the Memorial
Sloan-Kettering Cancer Center.
Yimin Qian, Ph.D., brings to Accutar Biotechnology over 20 years of drug discovery experiences in both Pharma and Biotech.
Yimin held multiple leadership positions previously. Most recently, he was Senior Director at Arvinas (2014-2018), Director & Asian lead at Merck (2013-2014) and Research Leader at Roche (1997-2013).
Yimin has published over 50 peer reviewed papers with over 3000 scientific citations. Yimin is an inventor of 29 issued U.S. patents and additional 26 pending patent applications.
At Accutar, Yimin will lead efforts to train AI drug discovery platform using expert human knowledge and to further improve Accutar-Degrader (Accurate-target degrader) technology platform.
Yimin obtained Ph.D. degree in organic chemistry from University of Pittsburgh. He received post-doc training from Yale University.
At Accutar, Xiangyan Sun leads a globally based team and oversees internal machine learning framework development with a focus on making significant progress in the application of artificial intelligence to drug discovery.
Xiangyan won the championship of 2014 Beauty of Programming Challenge, a programming competition for college students in Asia and sponsored by Microsoft in collaboration with the Institute of Electrical and Electronics Engineers (IEEE).
Xiangyan holds a B.S. and M.S. in Computer Science from Fudan University.